Inborn errors presenting with liver dysfunction
- PMID: 12069538
- DOI: 10.1053/siny.2001.0086
Inborn errors presenting with liver dysfunction
Abstract
In neonates, inborn errors of metabolism can produce all the major signs of liver dysfunction - jaundice, coagulopathy, hepatomegaly, splenomegaly, ascites and encephalopathy. The significance of encephalopathy in the neonate is different from that in older patients; it is usually due to a specific abnormality such as hypoglycaemia rather than being a non-specific indicator of liver failure. Attention is focused on five neonatal presentations: unconjugated hyperbilirubinaemia, cholestatic jaundice with otherwise good liver function, severe liver dysfunction (jaundice, coagulopathy persisting after vitamin K, and ascites), hepatomegaly with hypotonia+/- cardiomyopathy; and hepatosplenomegaly. The metabolic disorders presenting in these ways are listed alongside specific clinical features that can aid differential diagnosis and tests that can be used to confirm or refute the diagnosis. Diagnosis is important because treatment can be dramatically effective, e.g. withdrawal of galactose in galactosaemia. Even when treatment is not effective it is often possible to offer prenatal diagnosis for future pregnancies.
Copyright 2002 Published by Elsevier Science Ltd. All rights reserved.
Similar articles
-
[Diagnosis and acute treatment of inborn metabolic diseases in infants].Ugeskr Laeger. 2002 Nov 25;164(48):5613-9. Ugeskr Laeger. 2002. PMID: 12523004 Review. Danish.
-
Metabolic liver disease.Clin Res Hepatol Gastroenterol. 2012 Jun;36(3):287-90. doi: 10.1016/j.clinre.2012.03.028. Epub 2012 Apr 19. Clin Res Hepatol Gastroenterol. 2012. PMID: 22521124
-
Liver Disorders Caused by Inborn Errors of Metabolism.Endocr Metab Immune Disord Drug Targets. 2024;24(2):194-207. doi: 10.2174/1871530323666230623120935. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 37357514 Review.
-
Management and emergency treatments of neonates with a suspicion of inborn errors of metabolism.Semin Neonatol. 2002 Feb;7(1):17-26. doi: 10.1053/siny.2001.0084. Semin Neonatol. 2002. PMID: 12069535 Review.
-
Defects in bile acid biosynthesis--diagnosis and treatment.J Pediatr Gastroenterol Nutr. 2006 Jul;43 Suppl 1:S17-22. doi: 10.1097/01.mpg.0000226386.79483.7b. J Pediatr Gastroenterol Nutr. 2006. PMID: 16819396 Review.
Cited by
-
Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.J Inherit Metab Dis. 2017 Jul;40(4):497-517. doi: 10.1007/s10545-017-0053-3. Epub 2017 May 31. J Inherit Metab Dis. 2017. PMID: 28567541 Free PMC article. Review.
-
Environmental exposure as a risk-modifying factor in liver diseases: Knowns and unknowns.Acta Pharm Sin B. 2021 Dec;11(12):3768-3778. doi: 10.1016/j.apsb.2021.09.005. Epub 2021 Sep 10. Acta Pharm Sin B. 2021. PMID: 35024305 Free PMC article. Review.
-
Unlocking the potential: advancements and applications of gene therapy in severe disorders.Ann Med. 2025 Dec;57(1):2516697. doi: 10.1080/07853890.2025.2516697. Epub 2025 Jun 17. Ann Med. 2025. PMID: 40526097 Free PMC article. Review.
-
New management options for end-stage chronic liver disease and acute liver failure: potential for pediatric patients.Paediatr Drugs. 2006;8(1):1-13. doi: 10.2165/00148581-200608010-00001. Paediatr Drugs. 2006. PMID: 16494508 Review.
-
Inborn Errors of Metabolism in the Era of Untargeted Metabolomics and Lipidomics.Metabolites. 2019 Oct 21;9(10):242. doi: 10.3390/metabo9100242. Metabolites. 2019. PMID: 31640247 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical